Zhi-Hong Liu, M.D.

Quick facts

Marketed products

• tripterygium wilfordii · Immunology
  Tripterygium wilfordii extract suppresses immune cell activation and reduces inflammatory cytokine production through multiple pathways including NF-κB inhibition.

Phase 2 pipeline

• bortezominb and dexamethasone

Phase 1 pipeline

• Multi-target therapy
• Prednisone in full dose

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Zhi-Hong Liu, M.D. portfolio CI brief
• Zhi-Hong Liu, M.D. pipeline updates RSS